A CRISPR/CAS9-based strategy targets the personalized chimeric neosequence in fusion-driven cancer genome for precision medicine.

Huang, Wei; Zeng, Zhan-Cheng; Wang, Wen-Tao; Sun, Yu-Meng; Chen, Yue-Qin; Luo, Xue-Qun; Fang, Ke

Huang, Wei; Zeng, Zhan-Cheng; Wang, Wen-Tao; Sun, Yu-Meng; Chen, Yue-Qin; Luo, Xue-Qun; Fang, Ke.

Afiliación

Huang W; Key Laboratory of Gene Engineering of the Ministry of Education, School of Life sciences, Sun Yat-sen University, Guangzhou, China.
Zeng ZC; Key Laboratory of Gene Engineering of the Ministry of Education, School of Life sciences, Sun Yat-sen University, Guangzhou, China.
Wang WT; Key Laboratory of Gene Engineering of the Ministry of Education, School of Life sciences, Sun Yat-sen University, Guangzhou, China.
Sun YM; Key Laboratory of Gene Engineering of the Ministry of Education, School of Life sciences, Sun Yat-sen University, Guangzhou, China.
Chen YQ; Key Laboratory of Gene Engineering of the Ministry of Education, School of Life sciences, Sun Yat-sen University, Guangzhou, China.
Luo XQ; The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Fang K; Key Laboratory of Gene Engineering of the Ministry of Education, School of Life sciences, Sun Yat-sen University, Guangzhou, China.

Clin Transl Med ; 11(3): e355, 2021 03.

Article en En | MEDLINE | ID: mdl-33783997

Asunto(s)

Sistemas CRISPR-Cas/genética; Edición Génica/métodos; Fusión Génica/genética; Genoma/genética; Neoplasias/genética; Medicina de Precisión/métodos; Humanos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Genoma / Fusión Génica / Medicina de Precisión / Sistemas CRISPR-Cas / Edición Génica / Neoplasias Límite: Humans Idioma: En Revista: Clin Transl Med Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google